CD274 and neoplasm: Median OS in patients with PD-L1 expression on ≥ 50% of tumor cells treated with pembrolizumab in first-line treatment in clinical study KEYNOE-024 after 5 years of follow-up was 26.3 months (33.9 months in our study)21.